Fig. 5

Effects of single and combined MEK and RAF inhibition in patient-derived pancreatic organoids. a. Phase-contrast images showing an organoid formation assay. Organoids were seeded as singles cells and treated after 48 h with different doses of trametinib (10 nM,), dabrafenib (10 μM) and combination ratio 1:1000. Images were detected with EVOS Cell Imaging System (b). Patient-derived pancreatic organoid T1 (KRAS-mut) was incubated with dabrafenib and trametinib alone or in combination for 24 h. Protein lysate were analyzed by Western Blotting using p-ERK antibody. β-Actin is used as protein loading at blotting control. c. Patient-derived pancreatic organoid T1 was treated with increasing amounts of the dabrafenib (0.1–10 μM) alone or in combination with trametinib (01–10 nM) ratio 1:1000, for 72 h. Cell viability was evaluated by Cell Titer Glo 2.0 assay. The table shows the CI of trametinib and dabrafenib in a normal pancreatic organoid N1 and in 4 different PDAC organoids KRAS-mut